Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation

Although dual EGFR/HER2 tyrosine kinase inhibitor lapatinib has provided effective clinical benefits for HER2-positive breast cancer patients, acquired resistance to this drug remains a major concern. Thus, the development of alternative therapeutic strategies is urgently needed for patients who fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Thanh Kieu, Ho, Chien-Yi, Tsai, Chi-Hua, Wang, Chien-Kuo, Chen, Yun-Ju, Bau, Da-Tian, Tu, Chih-Yen, Li, Tzong-Shiun, Huang, Wei-Chien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801459/
https://www.ncbi.nlm.nih.gov/pubmed/31569723
http://dx.doi.org/10.3390/ijms20194812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801459/
https://www.ncbi.nlm.nih.gov/pubmed/31569723
http://dx.doi.org/10.3390/ijms20194812

Ejemplares similares